Unlike Semaglutide (GLP-1 only) or Tirzepatide (GLP-1 + GIP), Retatrutide activates three hormone pathwaysGLP-1, GIP, and glucagonleading to enhanced fat loss and energy expenditure
Vi tc dng, GHS c s dng nhiu trong iu tr cc bnh l nh tiu ng, vim gan, bnh tim, cc bnh l v ung th hay v suy gim min dch nh HIV/AIDS, nhim trng phi, Ci thin tp trung, gim cng thng No b b nh hng trc tip bi tc ng ca cc gc t do v mt s cht bo
10.1016/j.jmig.2007.06.003 136 YuL.SaileK.SwartzC
PMCID: PMC4885833
The addition of glucagon receptor activation increases energy expenditure and fat oxidation beyond what dual-agonist peptides can achieve alone
People monitoring their experience after starting tirzepatide should note that painful urination is not an expected medication effect